Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Actinium Pharmaceuticals Inc
ATNMCurrent price
1.71 USD
-0.08 USD (-4.47%)
Last closed
1.8 USD
Company
www.actiniumpharma.com
ISIN
US00507W2061
Sector
Healthcare
Industry
Biotechnology
Exchange
NYSE
Capitalization
59 896 128 USD
Yield for 12 month
-64.08 %
1Y
3Y
5Y
10Y
15Y
ATNM
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York. Address: 100 Park Avenue, New York, NY, United States, 10017
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
5.8 USDP/E ratio
–Dividend Yield
–Current Year
+81 000 USD
Last Year
+1 030 000 USD
Current Quarter
–
Last Quarter
–
Current Year
-709 000 USD
Last Year
+331 000 USD
Current Quarter
-189 000 USD
Last Quarter
-216 000 USD
Key Figures ATNM
1 year
3 years
5 years
10 years
EBITDA
-46 485 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-30.91 %
PEG Ratio
–
Return On Equity TTM
-87.96 %
Wall Street Target Price
5.8 USD
Revenue TTM
81 000 USD
Book Value
1.44 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100 %
Dividend Yield
–
Gross Profit TTM
1 030 000 USD
Earnings per share
-1.51 USD
Diluted Eps TTM
-1.51 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics ATNM
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ATNM
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:30
Payout Ratio
–
Last Split Date
11.08.2020
Dividend Date
11.08.2020
Stock Valuation ATNM
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
6.8399
Enterprise Value Revenue
1726.0705
Price Sales TTM
739.4584
Enterprise Value EBITDA
-3.6241
Price Book MRQ
1.3664
Financials ATNM
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ATNM
For 52 weeks
1.33 USD
10.24 USD
50 Day MA
1.8 USD
Shares Short Prior Month
2 268 875
200 Day MA
5.63 USD
Short Ratio
5.61
Shares Short
1 659 533
Short Percent
5.33 %
BeatStart